



This is a repository copy of *TRYMS : the ethical and practical considerations of a double-blind placebo controlled randomised clinical trial.*

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/154261/>

Version: Published Version

---

**Proceedings Paper:**

Swain, J., Smith, I., Smith, A. et al. (3 more authors) (2015) TRYMS : the ethical and practical considerations of a double-blind placebo controlled randomised clinical trial. In: *Trials. 3rd International Clinical Trials Methodology Conference, 16-17 Nov 2015, Glasgow, UK.* BioMed Central .

<https://doi.org/10.1186/1745-6215-16-S2-P200>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:  
<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

POSTER PRESENTATION

Open Access

# TRYMS: the ethical and practical considerations of a double-blind placebo controlled randomised clinical trial

Jayne Swain<sup>1</sup>, Isabelle Smith<sup>1\*</sup>, Alexandra Smith<sup>1</sup>, Jennifer Walsh<sup>2</sup>, Richard Ross<sup>2</sup>, Helen Marshall<sup>1</sup>

From 3rd International Clinical Trials Methodology Conference  
Glasgow, UK. 16-17 November 2015

A double blind randomised trial is the gold standard approach to minimise the introduction of bias from trial participants, healthcare professionals and clinical trial staff. Similarly, the use of a placebo is ideal when participant self-reported Quality of Life is one of the primary objectives. However, the combination of these trial design components can present challenging ethical and practical issues for good trial conduct.

TRYMS is a randomised, double-blinded, placebo controlled phase IV clinical trial in young male cancer survivors with low testosterone levels. The trial is designed to investigate whether testosterone treatment will result in a reduction of truncal fat mass and an increase in participant self-reported physical functioning scores and recruited 136 participants from 10 centres across the UK.

Practical issues relate to the potential for centre and trials unit staff to be unblinded by access to clinical data: for example, retests of testosterone measurements required for dose titration were required in the active arm but were done in the placebo arm to maintain the blind. Other issues relate to managing Investigational Medicinal Product supply requirements: a minimisation programme is used to ensure treatment groups are well-balanced by randomising centre however, a random element and participant replenishment halfway during treatment can result in a temporary skew to a centre's IMP requirements. The ethical issues relate to non-emergency requests for unblinding due to participant perception of treatment allocation.

Our experiences in TRYMS, along with our solutions, will be presented with considerations for the management of similar trials.

<sup>1</sup>Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK

Full list of author information is available at the end of the article

#### Authors' details

<sup>1</sup>Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK. <sup>2</sup>University of Sheffield, Sheffield, UK.

Published: 16 November 2015

doi:10.1186/1745-6215-16-S2-P200

**Cite this article as:** Swain *et al.*: TRYMS: the ethical and practical considerations of a double-blind placebo controlled randomised clinical trial. *Trials* 2015 **16**(Suppl 2):P200.

#### Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

